Published by
The Street
The Street
By GlobeNewswire Antiviral activity now confirmed against SARS-CoV-2 and all variants of concern including Omicron, Delta, Alpha, Beta and Gamma BOTHELL, Wash., Dec. 22, 2021 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that in vitro studies demonstrate its oral and intranasal/pulmonary SARS-CoV-2 main protease inhibitors exhibit antiviral potency against the Omicron variant. The Company earlier confirmed that its protease inhibitors demonstrated broad-spectrum antiviral activity against SARS-CoV-2 and all major previously identified varian…